Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial andin vitrostudies

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

(2011) J. Hoellenriegel et al.   BLOOD

Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein Phosphorylation in AML Blasts during a Clinical Trial Combining the mTOR Inhibitor Sirolimus and Intensive Chemotherapy

(2011) A. E. Perl et al.   CLINICAL CANCER RESEARCH

Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial

(2011) Paul G. Richardson et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer

(2011) Johanna C. Bendell et al.   JOURNAL OF CLINICAL ONCOLOGY

A Single Tube, Four-Color Flow Cytometry Assay for Evaluation of ZAP-70 and CD38 Expression in Chronic Lymphocytic Leukemia

(2010) Nagwa M. Hassanein et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia

(2010) I. M. Ghobrial et al.   CLINICAL CANCER RESEARCH

Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

(2010) Tadeusz Robak et al.   JOURNAL OF CLINICAL ONCOLOGY

LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells

(2010) Y M Mowery et al.   LEUKEMIA

Perifosine Inhibits Mammalian Target of Rapamycin Signaling through Facilitating Degradation of Major Components in the mTOR Axis and Induces Autophagy

(2009) L. Fu et al.   CANCER RESEARCH

Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group

(2009) Stephan Stilgenbauer et al.   JOURNAL OF CLINICAL ONCOLOGY

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD

Perifosine Synergistically Enhances TRAIL-Induced Myeloma Cell Apoptosis via Up-Regulation of Death Receptors

(2008) E. David et al.   CLINICAL CANCER RESEARCH

CLL cell apoptosis induced by nitric oxide synthase inhibitors: Correlation with lipid solubility and NOS1 dissociation constant

(2008) Marc C. Levesque et al.   LEUKEMIA RESEARCH

The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells

(2007) P. G. Longo et al.   BLOOD